Page 72 - Diamicron MR MIG Cycle 2(20-21) Final

dia bet es r esea rc h a nd cli n i c a l p r a cti ce 1 63 (2 020 ) 108 154

Contents available at ScienceDirect

Diabetes Research
and Clinical Practice

journal homepage: www.elsevier.com/locate/diabres

A real-world study in patients with type 2 diabetes

mellitus treated with gliclazide modified-release
during fasting: DIA-RAMADAN

b
c
e
d
Mohamed Hassanein a, * , Saud Al Sifri , Shehla Shaikh , Syed Abbas Raza , Javed Akram ,
i
h
f
g
Agung Pranoto , Achmad Rudijanto , Inass Shaltout , Md Fariduddin ,
j
a
Wan Mohd Izani Wan Mohamed , Fatheya Al Awadi , Thamer Alessa k
on behalf of the DIA-RAMADAN study investigators 1
a
Department of Endocrinology, Dubai Hospital, Dubai, United Arab Emirates
b
Al Hada Military Hospital, Taif, Saudi Arabia
c Department of Endocrinology, Saifee Hospital, Mumbai, Maharashtra, India
d
Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
e University of Health Sciences, Lahore, Pakistan
f
Department of Internal Medicine, Faculty of Medicine, Airlangga University/Dr. Soetomo Hospital, Surabaya, Indonesia
g Department of Internal Medicine, Faculty of Medicine, Brawijaya University/Dr. Saiful Anwar Hospital, Malang, Indonesia
h
Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt
i Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
j
Department of Medicine, Hospital Universiti Sains Malaysia, Kelantan, Malaysia
k Dasman Diabetes Institute, Kuwait City, Kuwait
A R T I C L E I N F O ABSTRA CT
Article history: Aims: To explore the real-world safety and effectiveness of gliclazide modified release (MR)
Received 3 February 2020 in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan.
Received in revised form Methods: DIA-RAMADAN (NCT04132934) was a prospective, international, observational
9 April 2020 study conducted in nine countries. Patients >18 years of age with T2DM (N = 1244) were
Accepted 10 April 2020 examined at an inclusion visit (V0) occurring 6–8 weeks before the start of Ramadan.
Available online 21 April 2020 Patients received a diary to report treatment changes, hypoglycaemic events (HEs), and
other adverse events. Gliclazide MR was taken once daily for 14–18 weeks. A second visit

* Corresponding author at: Department of Endocrinology, Dubai Hospital, Al Khaleej Street, Al Baraha, PO Box 7272, Dubai, United Arab
Emirates.
E-mail address: mhassanein148@hotmail.com (M. Hassanein).
1
Dr. Ahmad Gad, Dr. Rulli Rosandi, Dr. Ahmed Obyedallah, Dr. Seif Kamal, Dr. Albert Anwar Zaky, Dr. Soebagio Adi, Dr. Amr Aly, Dr.
Sony Wibisono, Dr. Ashraf Shaaban, Dr. Talaat Abd El Atty, Dr. Ashraf Shehata, Dr. K.D. Modi, Dr. Bahaa Sharaf El Deen, Dr. Kunal Kundan
, Dr. Benny Santosa, Dr. M.A. Sayem , Dr. Bowo Pramono, Dr. Mahboob Iftekhar , Dr. Budi Santoso, Dr. Maruf Bin Habib , Dr. Ehab Eltoraby,
Dr. Moazam, Dr. Essam Fathallah, Dr. Morshed Ahmed Khan , Dr. Fatimah Eliana, Dr. Nazma Akter , Dr. Franciscus Xaverius Suharnadi,
Dr. Nusrat Sultana , Dr. George Shaker, Dr. Shahjada Selim , Dr. Ghada Abdelrahman, Dr. Shahjamal Khan , Dr. Hendra Zufrie, Dr. Sharat S
Kolke, Dr. Himawan Sanusi, Dr. Sunil Dhand, Dr. Ida Ayu Khsanti, Dr. Supratik Bhattacharyya, Dr. Jeyakantha Ratnasingam , Dr. Syed
Nazim Ahmad, Dr. Kamal Karim, Dr. T.R. Sivagnanam, Dr. Laksmi Sasiarini, Dr. Yogesh Kadam, Dr. Makbul Aman, Dr. Eva
Niamuzisilawati, Dr. Mohab Abd El Hafez Taha, Prof. Azizul Hasan Aamir, Dr. Mohamed Abo El Maaty, Prof. Norlaila Mustafa, Dr.
Mohamed Anwar, Prof. Imtiaz Hasan, Dr. Mohammad Robikhul Ikhsan, Prof. Yakoob Ahmadani, Dr. Mohsen Khaled.
https://doi.org/10.1016/j.diabres.2020.108154
0168-8227/Ó 2020 The Author(s). Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).